- Home
- XBIO vs BIAF Comparison
XBIO vs BIAF Comparison
Compare XBIO & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIO | BIAF |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.8M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | XBIO | BIAF |
|---|---|---|
| Price | $2.08 | $1.17 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 35.9K | ★ 70.6K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,858,935.00 | ★ $6,776,739.00 |
| Revenue This Year | $1.99 | N/A |
| Revenue Next Year | $20.00 | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.30 | N/A |
| 52 Week Low | $1.90 | $1.13 |
| 52 Week High | $13.93 | $46.53 |
Technical Indicators
Market Signals| Indicator | XBIO | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 35.88 | 31.88 |
| Support Level | $1.90 | $1.18 |
| Resistance Level | $2.29 | $1.37 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 25.68 | 6.56 |
Price Performance
Historical ComparisonAbout XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.